The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2024 | The role of autoSCT in Hodgkin lymphoma
Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, discusses the role of autologous stem cell transplantation (autoSCT) in treating patients with Hodgkin lymphoma (HL) who relapse following frontline therapy. It is not yet clear whether non-transplant approaches hold potential for treating this patient population, and therefore, Dr Ansell highlights the need to administer a salvage regimen and proceed to autoSCT for the time being. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
